mild cases do not require any treatments anyway. AVIR was trying to monkey around, but it backfired. Now they have to redesign the trial, time is lost. Many other companies are working on similar treatments, end of the 2022 is a long time, in the meantime AVIR is dead money at the best. Don't try to catch a falling knife$Atea Pharmaceuticals, Inc.(AVIR)$
精彩评论